DULAGLUTIDE REDUCES HBA1C IRRESPECTIVE OF ANTIHYPERGLYCEMIC AGENTS, DURATION OF DIABETES, BMI AND WEIGHT LOSS: A POST HOC ANALYSIS FROM THE REWIND TRIAL
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32578-x
Abstract: In the REWIND CV outcomes trial, the addition of dulaglutide 1.5 mg (DU) vs placebo (PL) to standard of care reduced the composite risk of CV death, nonfatal MI and nonfatal stroke in patients with… read more here.
Keywords: antihyperglycemic agents; trial; reduces hba1c; irrespective antihyperglycemic ... See more keywords
Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States
Sign Up to like & getrecommendations! Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2085962
Abstract: Abstract Objective To report on the use of antihyperglycemic agents (AHAs) by age (i.e. read more here.
Keywords: cvd risk; patients t2d; risk; antihyperglycemic agents ... See more keywords
Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post‐transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Transplantation"
DOI: 10.1111/ctr.14922
Abstract: Uncontrolled type 2 diabetes mellitus (T2DM) and post‐transplant diabetes mellitus (PTDM) increase morbidity and mortality after kidney transplantation. Conventional strategies for diabetes management in this population include metformin, sulfonylureas, meglitinides and insulin. Limitations with these… read more here.
Keywords: novel antihyperglycemic; kidney; post transplant; diabetes mellitus ... See more keywords
1183-P: Utilization of Low vs. High Dose of Newer Antihyperglycemic Agents
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-1183-p
Abstract: Evidence from clinical trials suggest that newer antihyperglycemic agents (AHAs) have a better clinical profile at a higher dose. However, the utilization of the different doses in the real world is not well known. This… read more here.
Keywords: antihyperglycemic agents; high dose; newer antihyperglycemic; dose ... See more keywords